FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Delphi Management Partners VII, L.L.C. 2. Date of Event Requiring Statement (Month/Day/Year) 05/07/2014 3. Issuer Name and Ticker or Trading Symbol ALDER BIOPHARMACEUTICALS INC [ALDR] (Last) (First) (Middle) C/O DELPHI VENTURES, 3000 SAND HILL RD., BLDG. 1, SUITE 135 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) MENLO PARK, CA 94025 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Preferred Stock	  (1)	  (1)	Common Stock	2,083,541	$ (1)	I	By Delphi Ventures VII, L.P. (2)
Series D Preferred Stock	  (1)	  (1)	Common Stock	380,353	$ (1)	I	By Delphi Ventures VII, L.P. (2)
Series C Preferred Stock	  (1)	  (1)	Common Stock	20,835	$ (1)	I	By Delphi BioInvestments VII, L.P. (3)
Series D Preferred Stock	  (1)	  (1)	Common Stock	3,803	$ (1)	I	By Delphi BioInvestments VII, L.P. (3)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Delphi Management Partners VII, L.L.C. C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
DELPHI VENTURES VII L P 3000 SAND HILL ROAD BUILDING 1, SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
DELPHI BIOINVESTMENTS VII LP 3000 SAND HILL ROAD BUILDING 1, SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
ROEDER DOUGLAS A C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG., SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
DOUGLASS DAVID L C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
BOCHNOWSKI JAMES J C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	  X	Â	Â
PAKIANATHAN DEEPIKA C/O DELPHI VENTURES 3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CA 94025	  X	  X	Â	Â

Signatures

By: /s/ Matthew T. Potter, Attorney-in-Fact for: Delphi Management Partners VII, L.L.C. Delphi Ventures VII, L.P. Delphi BioInvestments VII, L.P. Deepika R. Pakianathan Douglas A. Roder David L. Douglass James J. Bochnowski		05/07/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The preferred stock is convertible at any time, at the holder's election, and has no expiration date. The preferred stock will automatically convert into common stock on a 1-to-1 basis upon closing of the initial public offering of the issuer.
(2)	The reported securities are directly owned by Delphi Ventures VII, L.P. ("DV VII"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of DV VII and may be deemed to have sole voting and dispositive power over the securities held by DV VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DV VII. Such persons and entities disclaim beneficial ownership of the securities held by DV VII, except to the extent of any pecuniary interest therein.
(3)	The reported securities are directly owned by Delphi BioInvestments VII, L.P. ("DBI VII"). DMP VII is the general partner of DBI VII and may be deemed to have sole voting and dispositive power over the securities held by DBI VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DBI VII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VII, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.